Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Is Up 6.1% After Revenue Growth and Slimmer Half-Year Losses - simplywall.st

Rhythm Pharmaceuticals (RYTM) Is Up 6.1% After Revenue Growth and Slimmer Half-Year Losses  simplywall.st

Rhythm Pharmaceuticals (RYTM) Is Up 6.1% After Revenue Growth and Slimmer Half-Year Losses - simplywall.st

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?  Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance  Stock Titan

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Click here to get full coverage on Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - Investor's Business Daily

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity  Investor's Business Daily

Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity - Investor's Business Daily

Click here to get full coverage on What Is Circadian Rhythm? - Sleep Foundation

What Is Circadian Rhythm?  Sleep Foundation

What Is Circadian Rhythm? - Sleep Foundation

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - Nasdaq

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?  Nasdaq

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects (RYTM) - Seeking Alpha

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects (RYTM)  Seeking Alpha

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects (RYTM) - Seeking Alpha

Click here to get full coverage on Rhythm Skateshop's "BPM" Video - Thrasher Magazine

Rhythm Skateshop's "BPM" Video  Thrasher Magazine

Rhythm Skateshop's "BPM" Video - Thrasher Magazine

Click here to get full coverage on Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term  Yahoo Finance

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance

Click here to get full coverage on Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability? - simplywall.st

Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability?  simplywall.st

Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability? - simplywall.st

Click here to get full coverage on Rare Disease Biotech Rhythm Pharmaceuticals Unveils $150M Stock Offering with Additional $22.5M Option - Stock Titan

Rare Disease Biotech Rhythm Pharmaceuticals Unveils $150M Stock Offering with Additional $22.5M Option  Stock Titan

Rare Disease Biotech Rhythm Pharmaceuticals Unveils $150M Stock Offering with Additional $22.5M Option - Stock Titan

Click here to get full coverage on Rhythm Pharma stock gains on obesity trial win (RYTM:NASDAQ) - Seeking Alpha

Rhythm Pharma stock gains on obesity trial win (RYTM:NASDAQ)  Seeking Alpha

Rhythm Pharma stock gains on obesity trial win (RYTM:NASDAQ) - Seeking Alpha

Click here to get full coverage on Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) - Yahoo Finance

Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)  Yahoo Finance

Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM) - Yahoo Finance

Click here to get full coverage on Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%  simplywall.st

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st

Click here to get full coverage on Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan

Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development  Stock Titan

Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan

Click here to get full coverage on RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - Yahoo Finance

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data  Yahoo Finance

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals nets $188.7M to fund IMCIVREE & pipeline - Stock Titan

Rhythm Pharmaceuticals nets $188.7M to fund IMCIVREE & pipeline  Stock Titan

Rhythm Pharmaceuticals nets $188.7M to fund IMCIVREE & pipeline - Stock Titan

Click here to get full coverage on Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline - Yahoo Finance

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline  Yahoo Finance

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ...  Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...  Yahoo Finance

Rhythm Pharmaceuticals Inc (RYTM) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals CFO Sells 42,120 Shares - The Motley Fool

Rhythm Pharmaceuticals CFO Sells 42,120 Shares  The Motley Fool

Rhythm Pharmaceuticals CFO Sells 42,120 Shares - The Motley Fool

Click here to get full coverage on Rhythm Pharmaceuticals to Reveal Crucial Phase 2 Data for Revolutionary Oral Obesity Treatment - Stock Titan

Rhythm Pharmaceuticals to Reveal Crucial Phase 2 Data for Revolutionary Oral Obesity Treatment  Stock Titan

Rhythm Pharmaceuticals to Reveal Crucial Phase 2 Data for Revolutionary Oral Obesity Treatment - Stock Titan

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock  GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Major Phase 3 Trial Results: New Hope for Hypothalamic Obesity Patients - Stock Titan

Major Phase 3 Trial Results: New Hope for Hypothalamic Obesity Patients  Stock Titan

Major Phase 3 Trial Results: New Hope for Hypothalamic Obesity Patients - Stock Titan

Click here to get full coverage on Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Yahoo Finance

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity  Yahoo Finance

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity - Yahoo Finance

Click here to get full coverage on Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains?  Yahoo Finance

Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - Yahoo Finance

Click here to get full coverage on Breakthrough: New Drug Achieves 19.8% Weight Loss in Rare Obesity Disorder Trial - Stock Titan

Breakthrough: New Drug Achieves 19.8% Weight Loss in Rare Obesity Disorder Trial  Stock Titan

Breakthrough: New Drug Achieves 19.8% Weight Loss in Rare Obesity Disorder Trial - Stock Titan

Click here to get full coverage on RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Zacks Investment Research

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study  Zacks Investment Research

RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Zacks Investment Research

Click here to get full coverage on Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ)  Seeking Alpha

Rhythm stock jumps as BofA upgrades on trial win (RYTM:NASDAQ) - Seeking Alpha

Click here to get full coverage on Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM)  Seeking Alpha

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market (RYTM) - Seeking Alpha

Click here to get full coverage on We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth - Yahoo Finance

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth  Yahoo Finance

We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth - Yahoo Finance

Click here to get full coverage on This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues - Investor's Business Daily

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues  Investor's Business Daily

This IBD 50 Biotech's Got 'Rhythm' — And Flashes 3 Telltale Clues - Investor's Business Daily

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates  Nasdaq

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Rhythm of the City: Swing Saturday - Museum of the City of New York

Rhythm of the City: Swing Saturday  Museum of the City of New York

Rhythm of the City: Swing Saturday - Museum of the City of New York

Click here to get full coverage on New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan

New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3  Stock Titan

New Clinical Data: Rhythm's Obesity Drug Achieves 23% Weight Loss in Real-World Study, FDA Filing Coming Q3 - Stock Titan

Click here to get full coverage on Rhythm Pharma TRANSCEND Trial Results: Breakthrough Data for Rare Obesity Coming at ENDO 2025 - Stock Titan

Rhythm Pharma TRANSCEND Trial Results: Breakthrough Data for Rare Obesity Coming at ENDO 2025  Stock Titan

Rhythm Pharma TRANSCEND Trial Results: Breakthrough Data for Rare Obesity Coming at ENDO 2025 - Stock Titan

Click here to get full coverage on $RYTM stock is up 7% today. Here's what we see in our data. - Nasdaq

$RYTM stock is up 7% today. Here's what we see in our data.  Nasdaq

$RYTM stock is up 7% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Rhythm Pharmaceuticals stock soars as Leerink raises price target on positive trial data - Investing.com

Rhythm Pharmaceuticals stock soars as Leerink raises price target on positive trial data  Investing.com

Rhythm Pharmaceuticals stock soars as Leerink raises price target on positive trial data - Investing.com

Click here to get full coverage on Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update  GlobeNewswire

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire

Click here to get full coverage on Novak Djokovic plays violin in US Open Asics ad: "Control the rhythm. Unlock the feeling" - Tennis.com

Novak Djokovic plays violin in US Open Asics ad: "Control the rhythm. Unlock the feeling"  Tennis.com

Novak Djokovic plays violin in US Open Asics ad: "Control the rhythm. Unlock the feeling" - Tennis.com

Click here to get full coverage on Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener

Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)  MarketScreener

Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener

Click here to get full coverage on Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - TipRanks

Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results  TipRanks

Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - TipRanks

Click here to get full coverage on Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock  GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic (NASDAQ:RYTM) - Seeking Alpha

Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic (NASDAQ:RYTM)  Seeking Alpha

Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic (NASDAQ:RYTM) - Seeking Alpha

Click here to get full coverage on AnMed Rhythm on the River - Anderson County South Carolina

AnMed Rhythm on the River  Anderson County South Carolina

AnMed Rhythm on the River - Anderson County South Carolina

Click here to get full coverage on Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have seen fantastic returns of 577% over the past three years - simplywall.st

Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have seen fantastic returns of 577% over the past three years  simplywall.st

Investors in Rhythm Pharmaceuticals (NASDAQ:RYTM) have seen fantastic returns of 577% over the past three years - simplywall.st

Click here to get full coverage on Pastel Parade Rhythm Game Launches on Steam on August 27 - Anime News Network

Pastel Parade Rhythm Game Launches on Steam on August 27  Anime News Network

Pastel Parade Rhythm Game Launches on Steam on August 27 - Anime News Network

Click here to get full coverage on Rhythm Pharmaceuticals Prices Public Offering Of 2.06 Mln Shares At $85 Per Share - Nasdaq

Rhythm Pharmaceuticals Prices Public Offering Of 2.06 Mln Shares At $85 Per Share  Nasdaq

Rhythm Pharmaceuticals Prices Public Offering Of 2.06 Mln Shares At $85 Per Share - Nasdaq

Click here to get full coverage on Rhythm & Brews - City of Hendersonville, NC (.gov)

Rhythm & Brews  City of Hendersonville, NC (.gov)

Rhythm & Brews - City of Hendersonville, NC (.gov)

Click here to get full coverage on Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - 富途牛牛

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term  富途牛牛

Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - 富途牛牛

Click here to get full coverage on Rhythm Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Rhythm Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90  Investor's Business Daily

Rhythm Pharmaceuticals Joins Rank Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Click here to get full coverage on Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM) - Seeking Alpha

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM)  Seeking Alpha

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven (NASDAQ:RYTM) - Seeking Alpha

Click here to get full coverage on RYTM Stocks in Spotlight: What’s Next? - timothysykes.com

RYTM Stocks in Spotlight: What’s Next?  timothysykes.com

RYTM Stocks in Spotlight: What’s Next? - timothysykes.com

Click here to get full coverage on WORK presents Mutual Rytm: ANNĒ, Lars Huismann, Measure Divide, & SHDW at TBA - Los Angeles, Los Angeles - Resident Advisor

WORK presents Mutual Rytm: ANNĒ, Lars Huismann, Measure Divide, & SHDW at TBA - Los Angeles, Los Angeles  Resident Advisor

WORK presents Mutual Rytm: ANNĒ, Lars Huismann, Measure Divide, & SHDW at TBA - Los Angeles, Los Angeles - Resident Advisor

Click here to get full coverage on Rhythm Pharmaceuticals stock price target raised to $130 by Citizens JMP - Investing.com

Rhythm Pharmaceuticals stock price target raised to $130 by Citizens JMP  Investing.com

Rhythm Pharmaceuticals stock price target raised to $130 by Citizens JMP - Investing.com

Click here to get full coverage on Insider Sale: Chief Scientific Officer of $RYTM Sells 1,313 Shares - Quiver Quantitative

Insider Sale: Chief Scientific Officer of $RYTM Sells 1,313 Shares  Quiver Quantitative

Insider Sale: Chief Scientific Officer of $RYTM Sells 1,313 Shares - Quiver Quantitative

Click here to get full coverage on Sensorimotor synchronization to rhythm in an experienced sea lion rivals that of humans | Scientific Reports - Nature

Sensorimotor synchronization to rhythm in an experienced sea lion rivals that of humans | Scientific Reports  Nature

Sensorimotor synchronization to rhythm in an experienced sea lion rivals that of humans | Scientific Reports - Nature

Click here to get full coverage on New Analyst Forecast: $RYTM Given $105.0 Price Target - Nasdaq

New Analyst Forecast: $RYTM Given $105.0 Price Target  Nasdaq

New Analyst Forecast: $RYTM Given $105.0 Price Target - Nasdaq

Click here to get full coverage on Rhythm Storm Review: glowing electronic beatdown! - Rogueliker

Rhythm Storm Review: glowing electronic beatdown!  Rogueliker

Rhythm Storm Review: glowing electronic beatdown! - Rogueliker

Click here to get full coverage on Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway  MedCity News

Rhythm Pharma Drug Lowers BMI in Rare Form of Obesity Rooted in a Dysregulated Brain Pathway - MedCity News

Click here to get full coverage on Chimpanzee drumming may give clues to the roots of rhythm - Science | AAAS

Chimpanzee drumming may give clues to the roots of rhythm  Science | AAAS

Chimpanzee drumming may give clues to the roots of rhythm - Science | AAAS

Click here to get full coverage on The role of syllabic rhythm in speech perception across languages - Nature

The role of syllabic rhythm in speech perception across languages  Nature

The role of syllabic rhythm in speech perception across languages - Nature

Click here to get full coverage on Rhythm And Bottles - bellingham.org

Rhythm And Bottles - bellingham.org

Click here to get full coverage on $RYTM stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

$RYTM stock is up 7% today. Here's what we see in our data.  Quiver Quantitative

$RYTM stock is up 7% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Finding His Rhythm: Robbie Dye’s First-Year Journey at WKU - Western Kentucky University

Finding His Rhythm: Robbie Dye’s First-Year Journey at WKU  Western Kentucky University

Finding His Rhythm: Robbie Dye’s First-Year Journey at WKU - Western Kentucky University

Click here to get full coverage on Rhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock up - Fierce Biotech

Rhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock up  Fierce Biotech

Rhythm’s phase 2 obesity pill trial hits primary endpoint, sending stock up - Fierce Biotech

Click here to get full coverage on Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025  GlobeNewswire

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025 - GlobeNewswire

Click here to get full coverage on Turns Out the Rhythm Genre in Gaming Has Been Alive All Along - I Just Underestimated the Indies - VICE

Turns Out the Rhythm Genre in Gaming Has Been Alive All Along - I Just Underestimated the Indies  VICE

Rhythm Pharmaceuticals Inc (RYTM)

Price Chart

Key Statistics

Technicals

About RYTM

Latest News

Rhythm Pharmaceuticals (RYTM) Is Up 6.1% After Revenue Growth and Slimmer Half-Year Losses - simplywall.st

Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar? - Yahoo Finance

Rhythm Pharmaceuticals Announces Q2 Earnings Date and Major Conference Appearance - Stock Titan

Advanced Charts

Top Gainers

Top Losers